These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3457769)

  • 1. Natural killer-cell immunodeficiency in patients with chronic myelogenous leukemia. I. Analysis of the defect using the monoclonal antibodies HNK-1 (LEU-7) and B73.1.
    Fujimiya Y; Bakke A; Chang WC; Linker-Israeli M; Udis B; Horwitz D; Pattengale PK
    Int J Cancer; 1986 May; 37(5):639-49. PubMed ID: 3457769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells.
    Fujimiya Y; Chang WC; Bakke A; Horwitz D; Pattengale PK
    Cancer Immunol Immunother; 1987; 24(3):213-20. PubMed ID: 3496152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. III. Defective interleukin-2 production by T-helper and natural killer cells.
    Chang WC; Fujimiya Y; Casteel N; Pattengale P
    Int J Cancer; 1989 Apr; 43(4):591-7. PubMed ID: 2522912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
    Chang WC; Hsiao MH; Pattengale PK
    Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with a deficiency of natural killer cell activity lack the VEP13-positive lymphocyte subpopulation.
    Ziegler-Heitbrock HW; Rumpold H; Kraft D; Wagenpfeil C; Munker R; Abo T; Balch CM; LeBien TW
    Blood; 1985 Jan; 65(1):65-70. PubMed ID: 3965053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of natural killer lymphocyte abnormalities in colon cancer patients.
    Balch CM; Tilden AB; Dougherty PA; Cloud GA; Abo T
    Surgery; 1984 Jan; 95(1):63-70. PubMed ID: 6581546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysis of fresh leukemic blasts by interferon-activated human natural killer cells.
    Pattengale PK; Sundstrom C; Yu AL; Levine A
    Nat Immun Cell Growth Regul; 1983-1984; 3(4):165-80. PubMed ID: 6597341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of human granular lymphocyte subpopulations expressing HNK-1 (Leu-7) and Leu-11 antigens in the blood and lymphoid tissues from fetuses, neonates and adults.
    Abo T; Miller CA; Balch CM
    Eur J Immunol; 1984 Jul; 14(7):616-23. PubMed ID: 6430709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia.
    Foa R; Lauria F; Lusso P; Giubellino MC; Fierro MT; Ferrando ML; Raspadori D; Matera L
    Br J Haematol; 1984 Nov; 58(3):509-16. PubMed ID: 6333890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocyte subpopulations in the neonate: high percentage of circulating B73.1+, HNK-1- cells.
    Montagna D; Ferremi P; Alberini C; Porta FA; de Amici M; Astaldi-Ricotti GC; Maccario R; Ugazio AG
    Thymus; 1986; 8(3):171-6. PubMed ID: 3750384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship of HNK-1 (Leu 7) and VEP13 antigens on human cells mediating natural killing.
    Rumpold H; Kraft D; Gastl G; Huber C
    Clin Exp Immunol; 1984 Sep; 57(3):703-9. PubMed ID: 6467685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer (NK)-cell activity in sorted subsets of peripheral blood mononuclear cells from patients with severe combined immunodeficiency.
    ten Berge RJ; Schellekens PT; Budding-Koppenol A; Dooren LJ; Vossen JM
    J Clin Immunol; 1987 May; 7(3):198-202. PubMed ID: 3597714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
    Karavodin LM; Golub SH
    Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a subset of human natural killer cells that express OKM1 but lack HNK-1 (Leu-7) antigens.
    Marolda R; Tilden AB; Abo T; Dougherty PA; Balch CM
    Scand J Immunol; 1984 Sep; 20(3):261-5. PubMed ID: 6238402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
    Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
    Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapidly expanded activated human killer cell clones have strong antitumor cell activity and have the surface phenotype of either T gamma, T-non-gamma, or null cells.
    van de Griend RJ; van Krimpen BA; Ronteltap CP; Bolhuis RL
    J Immunol; 1984 Jun; 132(6):3185-91. PubMed ID: 6233369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cell activity in childhood acute lymphoblastic leukaemia in remission.
    Dickinson AM; Proctor SJ; Jacobs E; Reid MM; Walker W; Craft AW; Kernahan J
    Br J Haematol; 1985 Jan; 59(1):45-53. PubMed ID: 3855649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cells in chronic leukemia. Function and markers.
    Sørskaar D; Førre O; Stavem P
    Int Arch Allergy Appl Immunol; 1988; 87(2):159-64. PubMed ID: 2973442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer lymphocytes in hairy cell leukemia: presence of phenotypically identifiable cells with defective functional activity.
    Smith BR; Rosenthal DS; Ault KA
    Exp Hematol; 1985 Mar; 13(3):189-93. PubMed ID: 3884356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on natural killer cells in chronic myeloid leukemia patients in remission.
    Dabholkar M; Tatake RJ; Advani S; Gangal SG
    Neoplasma; 1990; 37(1):47-53. PubMed ID: 1690865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.